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OBJECTIVE — Previous reviews of the effect of oral antidiabetic (OAD) agents on A1C levels
summarizedstudieswithvaryingdesignsandmethodologicalapproaches.Usingpredetermined
methodological criteria, we evaluated the effect of OAD agents on A1C levels.
RESEARCH DESIGN AND METHODS — The Excerpta Medica (EMBASE), the Med-
ical Literature Analysis and Retrieval System Online (MEDLINE), and the Cochrane Central
Register of Controlled Trials databases were searched from 1980 through May 2008. Reference
lists from systematic reviews, meta-analyses, and clinical practice guidelines were also reviewed.
Two evaluators independently selected and reviewed eligible studies.
RESULTS — A total of 61 trials reporting 103 comparisons met the selection criteria, which
included 26,367 study participants, 15,760 randomized to an intervention drug(s), and 10,607
randomized to placebo. Most OAD agents lowered A1C levels by 0.51.25%, whereas thia-
zolidinedionesandsulfonylureasloweredA1Clevelsby1.0–1.25%.Bymeta-regression,a1%
higher baseline A1C level predicted a 0.5 (95% CI 0.1–0.9) greater reduction in A1C levels after
6 months of OAD agent therapy. No clear effect of diabetes duration on the change in A1C with
therapy was noted.
CONCLUSIONS — The beneﬁt of initiating an OAD agent is most apparent within the ﬁrst
4to6months,withA1Clevelsunlikelytofallmorethan1.5%onaverage.PretreatedA1Clevels
have a modest effect on the fall of A1C levels in response to treatment.
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T
ype 2 diabetes is a chronic, progres-
sive disease that requires ongoing
attention to lifestyle and pharmaco-
therapy to achieve and maintain optimal
glucosecontrol(1).Declining-cellfunc-
tionandincreasinginsulinresistanceover
time lead to deteriorating glycemic con-
trol and the need for increasingly intense
pharmacotherapy(1).Glycemiccontrolis
achieved by lifestyle and pharmacother-
apy that targets fasting and postprandial
glucose levels, as well as A1C levels—a
measurement that reﬂects both fasting
and postprandial glucose concentrations
over a 3-month period (2).
Summaries of previous studies of oral
antidiabetic drugs (OADs) suggest that
they reduce A1C levels by 0.5–1.5% (2).
However, this estimated drop in A1C was
based on summaries of studies with vary-
ing designs, which may have led to over-
or underestimates of the true effect of
OADs.Thesesummariesincludedstudies
with varying completeness of follow-up
for both treatment and placebo groups,
use of placebo control subjects, sample
sizes, and durations of follow-up (3–6).
We therefore completed a systematic re-
view and meta-analysis of only those
studies that met predetermined method-
ological criteria to estimate the effect of
OADs on A1C levels.
RESEARCH DESIGN AND
METHODS
Search strategy
We searched all relevant biomedical da-
tabases, including the Medical Litera-
ture Analysis and Retrieval System
Online (MEDLINE), the Excerpta Medica
(EMBASE), and the Cochrane Central Reg-
ister of Controlled Trials. In consultation
with a medical librarian, we developed a
searchstrategybasedonananalysisofmed-
ical subject headings, terms, and key text
words from January 1980 to the present.
A start date of January 1980 was inten-
tionally chosen because A1C assays were
becoming routinely available in the early
1980s (7). We combined terms for ran-
domized controlled trials, placebo con-
trolled trials, type 2 diabetes, oral
hypoglycemics, OAD agents, and the
classes of OADs including -glucosidase
inhibitors (acarbose and miglitol), bigua-
nides (metformin), meglitinides (repa-
glinide and nateglinide), sulfonlyureas
(glyburide, glimepiride, glipizide, glu-
cotrol XL, gliclazide, and gliclazide MR),
thiazolidinediones (TZDs) (rosiglitazone
and pioglitazone), and dipeptidyl pepti-
dase-4 (DPP-4) inhibitors (sitagliptin and
vildagliptin) (2). Reference lists from rel-
evant meta-analyses, systematic reviews,
and clinical guidelines were also exam-
ined.OnlineAppendixFig.1(availablein
an online appendix at http://care.
diabetesjournals.org/cgi/content/full/
dc09-1727) shows the search and selec-
tion process.
Study selection
All citations retrieved were reviewed
against predetermined eligibility criteria.
To be included, studies had to written
in English, in a peer-reviewed journal
between January 1980 and May 2008,
and meet the following criteria: 1)b ea
randomized, double-blind, placebo-
controlled trial; 2) report data on non-
pregnant participants aged 18 and older
with type 2 diabetes; 3) report the differ-
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada; the
2Women’s Col-
lege Hospital, University of Toronto, Toronto, Ontario, Canada; the
3Centre for Evaluation of Medicines,
St. Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada; and the
4Department of Clinical Epidemi-
ology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Corresponding author: Diana Sherifali, dsherif@mcmaster.ca.
Received 16 September 2009 and accepted 5 May 2010. Published ahead of print at http://care.
diabetesjournals.org on 18 May 2010. DOI: 10.2337/dc09-1727.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Reviews/Commentaries/ADA Statements
META-ANALYSIS
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1859ential effect of the addition of an OAD
versusplaceboontheA1Clevel;4)report
the effect of a single OAD versus placebo
in subjects who were either drug naïve or
on background therapy with an OAD
and/or insulin; 5) include at least 50 sub-
jects in each arm; and 6) report the effect
oftherapyontheA1Clevelinatleast70%
of the randomized participants after a
minimum of 12 weeks in every arm of the
study (placebo and treatment arms).
Studies were excluded if: 1) they reported
data on subjects who did not have type 2
diabetes; 2) they reported data from ﬁrst-
generation sulfonylurea drugs or OADs
withdrawnforsafetyreasonsinanycoun-
try; 3) the intervention included the initi-
ationoftwoOADagentsatthesametime;
or 4) there was no statement that in-
formed consent was obtained.
Data extraction
Two investigators (D.S. and K.N.) inde-
pendently reviewed the titles, abstracts,
and full articles for inclusion by using
standardized forms. Discrepancies in eli-
gibilitywerediscussedbetweenreviewers
until agreement was achieved. Data ab-
straction was independently completed
by two authors (D.S. and K.N.) and com-
pared for accuracy. Items abstracted per-
tained to study characteristics, patient
characteristics, and outcome results. As
the main objective of this review and
meta-analysis was to determine the effec-
tiveness of OADs on A1C levels, rates of
adverse events and hypoglycemia were
not considered. The complete list of data
abstracted is described in Online Appen-
dix Table 1. A1C levels that were ab-
stracted were those derived from any
randomized subject who had an A1C
level done within any given time interval.
Unadjusted mean differences in A1C lev-
elswerecollected.Authorswerealsocon-
tacted for further clariﬁcation regarding
follow-up data at various time intervals
and A1C values.
Statistical analysis
Data were categorized in the following
time intervals after randomization: 12;
13–18; 19–24; 25–39; 40–47; 48–55;
and 56–104 weeks. The mean difference
between baseline to follow-up A1C levels
at all available time intervals as well as
measures of dispersion for placebo and
treatment arms were recorded. If mean
differences were not reported, a differ-
ence in means was calculated from the
reported mean baseline and end point
A1C values. A1C levels were abstracted
from the text or tables, read from graphs,
or computed. When more than one
method for reporting the A1C level was
used,thelevelreportedinthetextortable
was used. When only the proportional
mean decrease in A1C was provided for
placebo and treatment arms, an end of
study A1C level was calculated. All mea-
sures of dispersion were converted to
SDs. When SDs were not reported, esti-
matedbaselineandﬁnalSDswerederived
from data from other studies at the same
time interval.
When more than one comparison
arm was available for a speciﬁc drug and
dose, a meta-analysis was completed at
the reported time interval. As the focus of
this review was on the glucose effect of
different classes of drugs and not individ-
ual drugs, the results of different drugs
and doses from the same class were meta-
analyzed to yield an overall estimate.
Cochran Q test and I-squared statistics
were calculated for heterogeneity. If there
was heterogeneity, pooled effects were
calculated using a random-effects model
(8).
A meta-regression analysis was also
completed at each available time interval
where there was sufﬁcient data to assess
the effect of baseline A1C and diabetes
duration on the fall of A1C with OAD
therapy.Forthisequation,thedependent
variable was change in A1C, and the in-
dependent variables included: 1) drug
class;2)dose;3)diabetesduration;and4)
baseline A1C. The dose variable in the re-
gression equation was treated categori-
cally with the starting dose coded as the
baseline amount, and each doubling of a
drug dose was a single increment in-
crease. Agreement kappa statistics for
each state of eligibility assessment were
calculated using PC-Agree (McMaster
University, Hamilton, Ontario, Canada)
software. All statistical analyses were
done using STATA statistical software
(version 10.0) (StataCorp, College Sta-
tion, TX).
RESULTS
Study and patient characteristics
A total of 61 studies comprising 103 dif-
ferent comparisons of OADs met the in-
clusion criteria. Thirty (49%) were found
in EMBASE (Online Appendix references
1–30); 21 (34%) were found in the Coch-
rane Central Register of Controlled Trials
(OnlineAppendixreferences31–51);and
10 (16%) were found in MEDLINE (On-
line Appendix references 52–61). The
studies were published between 1994
and 2008 with 79% of the studies pub-
lished on or after 2000. Eligibility agree-
ment was assessed between reviewers
using a Cohen’s  coefﬁcient and was 0.8
for title and abstract review and 0.8 for
full article review. TZDs studies ac-
counted for the greatest number of tri-
als(n27),followedbyDPP-4inhibitors
(n  26), alpha glucosidase inhibitors
(n  22), biguanides (n  12), meglitin-
ides (n  10), and sulfonylureas (n  6).
Thedurationofstudiesrangedfrom12to
156 weeks; 74% ranged from 12 to 24
weeks; 20% ranged from 25 to 52 weeks;
and 6% exceeded 52 weeks. Funding
sources for the trials included private for
proﬁt (73%); government, private for
proﬁt, and/or private not for proﬁt (9%);
and 18% of the studies did not report
their funding source (Online Appendix
Table 2).
Thetrialsenrolledacombinedtotalof
26,367 patients with 15,760 randomized
to an intervention drug and 10,607 ran-
domizedtoplacebo.Backgrounddiabetes
treatment in the studies included one or
more OADs in 25 studies (41%); OAD
plusinsulintherapyinthreestudies(5%);
and insulin only in six of the studies
(10%). In 10 studies (16%), the subjects
discontinued OAD therapy prior to ran-
domization, and in 17 studies (28%), the
subjects were drug naïve. Study subjects
had a median age of 57 years (range
52–69 years of age) and were more likely
to be male (median 57%, range 39–84).
ThemedianbaselineA1Cacrossthestudy
populations was 8.3% (range 6.6–10%),
and similar baseline A1C levels were seen
across drug naïve patient groups (median
8.2, range 6.6–9.2), those on OAD(s) or
discontinued OAD(s) (median 8.2, range
6.7–10)andpatientpopulationsusingin-
sulin (median 8.8, range 7.8–9.9). The
median BMI was 30 (range 24–34) and
the median duration of diabetes was 5
years (range 1.4–14 years of age) (Online
Appendix Table 3).
OAD class effectiveness
Alpha glucosidase inhibitors. We iden-
tiﬁed 15 comparisons of acarbose and 6
comparisons of miglitol for which the ef-
fect on A1C for up to 2 years were re-
ported (Fig. 1) (Fig. 2) (Online Appendix
Figs. 2–7). All doses of both drugs, rang-
ing from 75 to 900 mg per day, reduced
A1Clevelscomparedwithplacebo.Doses
of 150 mg per day or higher achieved an
A1C reduction of 1% versus placebo
with no evidence of an incremental effect
OAD agents effect on A1C levels
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drugs persisted for up to 2 years (Fig. 2)
(Online Appendix Figs. 2–7).
Biguanides. There were seven compari-
sons of metformin and ﬁve comparisons of
long-acting metformin versus placebo that
assessed doses ranging from 500 to 2,550
mgperdayforupto10months(Figs.1and
2) (Online Appendix Figs. 3 and 4). Doses
up to 1,500 mg per day reduced A1C levels
by 1% compared with placebo after 3
monthsoftherapy.Therewaslittleevidence
for additional reduction at higher doses,
and the effect persisted for at least 10
months after treatment was begun.
Figure 1—Treatment effect by OAD class at 13–18 weeks. Each line represents a treatment effect (F) and 95% CIs (ends of the line). The diamond
shape represents a meta-analyzed mean difference for a particular OAD class and dose. *Illustrates the generally accepted maximum daily dose. A,
acarbose; Gm, glimepiride; Gp, glipizide; Gy, glyburide; M, miglitol; Me, metformin; Ml, metformin (long-acting); N, nateglinide; P, pioglitazone;
R, rosiglitazone; Re, repaglinide; S, sitagliptin; V, vildagliptin.
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isons of sitagliptin and 7 comparisons of
vildagliptin were identiﬁed in which the
effect on A1C for up to 1 year were re-
ported (Figs. 1 and 2) (Online Appendix
Figs. 2–6). All doses of both drugs, rang-
ing from 10 to 200 mg per day, reduced
A1Clevelscomparedwithplacebo.Doses
of 100 mg per day or higher achieved an
A1Creductionof0.75%versusplacebo
with no evidence of an incremental effect
beyond that dose.
Meglitinides. We found eight compari-
sons of nateglinide with doses ranging
from 90 to 540 mg per day and one com-
parison of repaglinide at 3 mg per day
versus placebo for up to 6 months in du-
ration. Doses up to 360 mg per day re-
duced A1C levels by 0.75% compared
with placebo after 3 months of therapy.
There was little evidence for additional
reduction at higher doses (Figs. 1 and 2)
(Online Appendix Figs. 2 and 3).
Sulfonylureas. Our search identiﬁed
three comparisons of glipizide (doses
ranging from 2.5 to 20 mg per day), two
ofglimepiride(dosesrangingfrom8to16
mg per day), and one of glyburide (20 mg
per day) for which the effect on A1C for
up to 2 years was reported (Figs. 1 and 2)
(Online Appendix Figs. 2–7). As indi-
cated in Fig. 2, doses 8 mg per day of
glimepiridegenerallyachievedanA1Cre-
duction of 1.25% versus placebo. The
studies suggested that the effect of these
drugs persisted for at least 2 years (Fig. 2)
(Online Appendix Figs. 2–7).
TZDs. We identiﬁed 17 comparisons of
rosiglitazone and 10 comparisons of pio-
glitazone for which the effect on A1C for
up to 1 year were reported (Figs. 1 and 2)
(Online Appendix Figs. 2–4, 6). One
low-dose study of rosiglitazone assessing
doses of 0.1, 0.5, and 2 mg per day did
not show any effect on A1C levels. Daily
doses of 4–8 mg of rosiglitazone and
15–45 mg of pioglitazone reduced A1C
levels compared with placebo. Rosiglita-
zone at 8 mg per day achieved an A1C
reductionof1.25%versusplacebo,and
pioglitazoneat30mgperdayachievedan
A1C reduction of 1% versus placebo
(Fig. 2). The effect of these drugs per-
sisted for at least 1 year in these studies
(Fig. 2) (Online Appendix Figs. 2–4, 6).
The effect of baseline A1C and
diabetes duration levels on the fall
of A1C
After adjusting for drug class, dose, dia-
betes duration, and baseline A1C in the
meta-regression analysis, the addition of
anOADledtoa0.2–0.5%greaterdecline
forevery1%higherbaselineA1Clevel.As
noted in Table 1 (Table 1), this effect was
statistically signiﬁcant beyond 13 weeks.
No consistent effect of diabetes duration
on the change in A1C was noted. Insufﬁ-
cient data regarding diabetes duration
precludedestimatingtheeffectofdiabetes
duration and baseline A1C in studies of
40 or more weeks’ duration. The effect of
baseline A1C on the change in A1C with
therapycouldnotbeadjustedforchanges
Figure 2—Treatment effects on A1C by OAD class, dose, and time. Error bars represent 95% CIs. F, represent pooled, weighted mean differences.
E, represent individual comparison treatment effects. *Treatment effect 1.1 (95% CI 0.8–1.4). †Illustrates the generally accepted maximum daily
dose. A, acarbose; AG-, glucosidase inhibitors; Gm, glimepiride; Gp, glipizide; Gy, glyburide; M, miglitol; Me, metformin; Ml, metformin (long-
acting); N, nateglinide; P, pioglitazone; R, rosiglitazone; Re, repaglinide; S, sitagliptin; V, vildagliptin.
OAD agents effect on A1C levels
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insulin doses were not always recorded.
CONCLUSIONS — This systematic
review and meta-analysis of double-
blind, randomized controlled trials that
met predeﬁned methodological criteria
summarizedtreatmenteffectsonA1Clev-
els across OAD drug class, dose, and du-
ration of therapy (Fig. 2). The greatest
pooled treatment effect noted was with
maximum doses of sulfonylureas after 12
weeks of therapy, followed by TZDs after
13–18 weeks of therapy. Across all OAD
classes, an increase in dose yielded a
further decrease in A1C initially with a
maximum effect achieved by 3–6
months.
The meta-regression analysis also
providedanumericalestimateofaneffect
that has been commented on by previous
authors: higher baseline A1C levels are
associated with greater declines in A1C
withtherapy(9).However,thiseffectwas
modest in most studies that were re-
viewed, such that after controlling for
OAD drug class and dose, every 1%
higher pretreatment A1C levels predicted
a 0.5% greater fall of A1C levels after 6
months of therapy.
This review has several strengths.
First,itwasrestrictedtorandomizedcon-
trolled trials that met predetermined
methodological criteria to minimize the
potentialforbias.Ofnote,theapplication
ofthesecriterialedtotheexclusionof150
out of 211 (71%) manuscripts that may
otherwise have been included. Second, it
entailed a comprehensive search for all
currently used OAD classes for type 2 di-
abetes treatment. Third, the effect of
OADsonA1Clevelwasassessedatdiffer-
ent time intervals, ranging from 12 weeks
to 2 years. Finally, it focused on the effect
of OAD class versus individual drugs and
therefore may be relevant to new drugs
from the same class.
This review has several limitations.
First, most of the studies included partic-
ipantswithrelativelynewlydiagnoseddi-
abetes(mediandurationofdiabetesof5.2
years). As such, the review’s ﬁndings may
not be relevant to patients with a longer
duration of diabetes or with diabetes-
related complications. Second, relatively
few studies were available for sulfonyl-
ureas (n  6), meglitinides (n  10), and
biguanides (n  12) thereby affecting the
reliability of their respective quantitative
estimates. Third, less than 30% of the re-
viewed papers reported the effect of ther-
apy for periods greater than 24 weeks.
Fourth, there is some statistical heteroge-
neity (ranging up to 90%) in the meta-
analyzed results of the included studies,
regardless of OAD class, drug, or dose.
This heterogeneity may have been due to
studydifferencesindesign,patientdemo-
graphics and characteristics, duration of
diabetes, and background drug therapy
or confounding. Regardless of the cause,
heterogeneity was managed by using a
random-effects model for meta-analyses.
Fifth, some of the summarized trials
added oral agents to background therapy
that included insulin. If investigators ad-
justed the dose of insulin during the trial,
this may have affected the estimate of the
effect of the OAD on the change in A1C.
This could not be taken into consider-
ation as insulin doses were not provided
in the reports. Finally, it is possible that
this review was inﬂuenced by publication
bias given that studies with positive re-
sults are generally more likely to get pub-
lished, resulting in an overestimate of the
beneﬁt of an OAD on A1C reduction.
In summary, the results of this sys-
tematic review and meta-analysis suggest
that the initiation of an OAD in addition
tocurrenttherapyyieldsanadditionalde-
crease in A1C level of 1–1.25% with
most of the treatment effect evident by
3–6 months of initiating OAD therapy.
This effect was fairly consistent between
OADclasseswithsulfonylureasandTZDs
having the greatest reduction in AIC. The
meta-regression analysis numerically
demonstrated a small effect of baseline
A1C on the fall of A1C with OAD treat-
ment. Further carefully conducted OAD
trials are needed to account for 1) combi-
nations of OAD drug use and its impact
onA1Clevels;2)theeffectivenessoflong-
term OAD use on A1C levels; and 3) ad-
verse and hypoglycemic events.
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